Literature DB >> 26481226

Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

Gianluigi Taverna1, Giorgio Bozzini2, Fabio Grizzi3, Mauro Seveso2, Alberto Mandressi2, Luca Balzarini4, Federica Mrakic4, Pietro Bono2, Oliviero De Franceco2, NicolòMaria Buffi5, Giovanni Lughezzani5, Massimo Lazzeri5, Paolo Casale5, Giorgio Ferruccio Guazzoni5.   

Abstract

PURPOSE: To investigate prostate cancer (PC) detection rate, employing endorectal multiparametric 3-tesla magnetic resonance imaging (MRI) driving subsequent cognitive systematic prostatic biopsy (CSPB) versus a homogenous group of patients who did not undergo endorectal MRI.
MATERIALS AND METHODS: A series of patients with a first negative biopsy were enrolled in the study. Patients were randomized into two groups: Group A: patients underwent MRI and subsequent CSPB; Group B: patients that did not undergo MRI. Each patient underwent a 13-core sampling. Patients from Group A had four cores more for each MRI suspected lesion. The cancer detection rate was calculated for each group with regard to possible matches or mismatches between MRI evidence and pathological reports.
RESULTS: Two hundred consecutive patients were investigated. Fifty out of 200 (25 %) patients had a diagnosis of PC, 24 in Group A and 26 in Group B. In Group A, 67 patients (67 %) were positive for suspected lesions at the MRI. The mismatch between MRI findings and the CSPB outcome was 61 % with an MRI-driven detection rate of 15 %. Group B detection rate was 26 % with no significant differences versus Group A (P = NS). Patient discomfort was higher in Group A (82 %). The accuracy of CSPB was 41 % with a positive predictive value of 22.3 %. This rate is lower in high-grade cancers (11.9 %). The cost-effectiveness was higher in Group A.
CONCLUSIONS: Prostate cancer detection rate does not improve by CSPB. The accuracy of CSPB was lower in high-grade PC, and a higher cost was found with CSPB.

Entities:  

Keywords:  Detection rate; Magnetic resonance imaging; Prostate biopsy; Prostate cancer

Mesh:

Year:  2015        PMID: 26481226     DOI: 10.1007/s00345-015-1711-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  34 in total

1.  PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients.

Authors:  V Serretta; A Catanese; G Daricello; R Liotta; R Allegro; A Martorana; F Aragona; D Melloni
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-07-17       Impact factor: 5.554

2.  Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation.

Authors:  L Hoekx; W Jeuris; E Van Marck; J J Wyndaele
Journal:  Acta Urol Belg       Date:  1998-10

Review 3.  The role of color Doppler and staging biopsies in prostate cancer detection.

Authors:  R L Bree
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

4.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

5.  Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.

Authors:  Daniel Junker; Michael Quentin; Udo Nagele; Michael Edlinger; Jonathan Richenberg; Georg Schaefer; Michael Ladurner; Werner Jaschke; Wolfgang Horninger; Friedrich Aigner
Journal:  World J Urol       Date:  2014-08-01       Impact factor: 4.226

Review 6.  The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review.

Authors:  Maudy Gayet; Anouk van der Aa; Harrie P Beerlage; Bart Ph Schrier; Peter F A Mulders; Hessel Wijkstra
Journal:  BJU Int       Date:  2015-08-28       Impact factor: 5.588

Review 7.  PI-RADS version 2: what you need to know.

Authors:  T Barrett; B Turkbey; P L Choyke
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

8.  Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies.

Authors:  Tillmann Loch
Journal:  World J Urol       Date:  2007-08-11       Impact factor: 4.226

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  Impact of Real-Time Elastography versus Systematic Prostate Biopsy Method on Cancer Detection Rate in Men with a Serum Prostate-Specific Antigen between 2.5 and 10 ng/mL.

Authors:  Gianluigi Taverna; Paola Magnoni; Guido Giusti; Mauro Seveso; Alessio Benetti; Rodolfo Hurle; Piergiuseppe Colombo; Francesco Minuti; Fabio Grizzi; Pierpaolo Graziotti
Journal:  ISRN Oncol       Date:  2013-01-16
View more
  3 in total

1.  Targeted 11C-choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy.

Authors:  Massimo Lazzeri; Egesta Lopci; Giovanni Lughezzani; Piergiuseppe Colombo; Paolo Casale; Rodolfo Hurle; Alberto Saita; Lorenzo Leonardi; Giuliana Lista; Roberto Peschechera; Luisa Pasini; Marcello Rodari; Silvia Zandegiacomo; Alessio Benetti; Pasquale Cardone; Federica Mrakic; Luca Balzarini; Arturo Chiti; Giorgio Guazzoni; Nicolò Maria Buffi
Journal:  Eur J Hybrid Imaging       Date:  2017-11-01

2.  Optimal biopsy strategy for prostate cancer detection by performing a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Yi Wang; Jundong Zhu; Zhiqiang Qin; Yamin Wang; Chen Chen; Yichun Wang; Xiang Zhou; Qijie Zhang; Xianghu Meng; Ninghong Song
Journal:  J Cancer       Date:  2018-06-05       Impact factor: 4.207

Review 3.  Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.

Authors:  Niklas Harland; Arnulf Stenzl; Tilman Todenhöfer
Journal:  World J Mens Health       Date:  2020-06-24       Impact factor: 5.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.